文献速递慢性肾脏病

尿微胆固醇与CKD不良肾脏结局的关联

Urinary Microcholesterol and Adverse Kidney Outcomes in CKD.
PubMed 文献 · Kidney Int Rep · 2026-04-21

结果显示U-mCHO最高四分位组MAKE50风险显著升高(校正HR 7.30,95%CI 2.74-19.49),低蛋白尿患者中MAKE30风险亦升高(HR 3.06,95%CI 1.37-6.85)。

要点

  • U-mCHO最高四分位组MAKE50风险为最低组的7.30倍(95%CI 2.74-19.49)。
  • 低蛋白尿(UPCR<0.5 g/g)患者中U-mCHO与MAKE30相关(HR 3.06,95%CI 1.37-6.85)。
  • 蛋白尿水平对上述关联无交互作用(P=0.89),支持U-mCHO作为肾脏脂质损伤的无创标志物。

核心结论

  • U-mCHO与CKD患者MAKE50独立相关,并在低蛋白尿患者中与MAKE30相关,支持其作为肾脏脂质损伤的潜在无创生物标志物。

主要发现

  • U-mCHO平均值为3.0±5.8 mg/g肌酐。
  • U-mCHO最高四分位组MAKE50风险显著高于最低四分位组(校正HR 7.30,95%CI 2.74-19.49)。
  • 以对数转换连续变量建模时关联一致。
  • 低蛋白尿(UPCR<0.5 g/g)患者中U-mCHO与MAKE30相关(HR 3.06,95%CI 1.37-6.85)。
  • 蛋白尿水平无交互作用(P=0.89)。

关键数值与推荐

  • 主要结局MAKE50定义为eGFR下降≥50%、启动肾脏替代治疗(KRT)或肾脏相关死亡的复合终点。
  • 亚组替代结局MAKE30定义为eGFR下降30%的复合终点。
  • U-mCHO最高vs最低四分位MAKE50的校正HR为7.30(95%CI 2.74-19.49)。
  • 低蛋白尿患者MAKE30的HR为3.06(95%CI 1.37-6.85)。

临床怎么用

  • 在CKD患者中可考虑检测尿微胆固醇以辅助风险评估,尤其对蛋白尿不明显的患者可能提供额外预后信息。

局限性

  • 原文摘要未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Urinary microcholesterol (U-mCHO) may reflect tubular or glomerular injury through impaired lipid handling; nonetheless, its prognostic value in chronic kidney disease (CKD) remains unclear. We examined whether U-mCHO is associated with adverse kidney outcomes. METHODS: We conducted a cohort study of patients with CKD (baseline eGFR ≥ 15 ml/min per 1.73 m2), among whom baseline U-mCHO was measured between April 2022 and July 2022 and who were followed until December 2025. The primary outcome was major adverse kidney events (MAKE) with a 50% estimated glomerular filtration rate (eGFR) decline (MAKE50), defined as a composite of a ≥ 50% reduction in eGFR, initiation of kidney replacement therapy (KRT), or kidney-related death. Associations were evaluated using multivariable Cox models. Subgroup analyses focused on patients with low proteinuria (urinary protein-to-creatinine ratio [UPCR] < 0.5 g/g) using an alternative composite outcome (MAKE30) based on a 30% decline in eGFR. RESULTS: A total of 1562 patients were included. The mean U-mCHO level was 3.0 ± 5.8 mg/g creatinine. Higher U-mCHO levels were associated with greater MAKE50 risk (adjusted hazard ratio [HR] for highest vs. lowest quartile: 7.30; 95% confidence interval [CI]: 2.74-19.49). This association was consistent when U-mCHO was modeled as a log-transformed continuous variable. The association remained consistent across subgroups and persisted in patients with low proteinuria (HR for MAKE30: 3.06; 95% CI: 1.37-6.85), with no interaction by proteinuria level (P = 0.89). CONCLUSION: U-mCHO is independently associated with MAKE50 in CKD. The association with MAKE30 was also observed in patients with low proteinuria, supporting U-mCHO as a potential noninvasive biomarker of kidney lipid injury.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Furuta H, Umeda R, Hoshi M, et al. Urinary Microcholesterol and Adverse Kidney Outcomes in CKD. Kidney Int Rep. 2026. PMID: 42318537. doi:10.1016/j.ekir.2026.106549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。